TrianglePembrolizumab (NCT06493019)
Pembrolizumab trial for Anal Cancer (NCT06493019). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with untreated, selected stage I–III anal squamous-cell cancer who cannot receive standard fluorouracil/mitomycin chemoradiation. Stage IIIB/C tumors must be smaller than five centimeters.
The idea: combine radiation with weekly carboplatin and paclitaxel for six weeks, plus pembrolizumab in weeks one and four. Pembrolizumab blocks PD-1 to support T-cell attacks on cancer. Eight maintenance pembrolizumab cycles follow, six weeks apart. Researchers measure complete clinical response at six months. Tumor tissue is required.
This phase 2 study plans 23 patients. Dustin Deming leads five recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.